Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.71 |
| ▸ | HTR2C | P28335 | 4/20 | 0.71 |
| ▸ | HTR2B | P41595 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732778 | 1.00 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL29633115 | 0.84 | HTR2A (0.72) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL20450791 | 0.84 | HTR2A (0.72) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL25541553 | 0.83 | HTR2A (0.70) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| Psilocybin SCHEMBL20898148 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL28843177 | 0.83 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL25802778 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL31742680 | 0.83 | HTR2A (0.70) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| Psilocybin SCHEMBL158945 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| Psilocybin SCHEMBL25186846 | 0.82 | HTR2A (0.98) | HTR2AHTR2CHTR2BHTR1AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426818-A2 | METHODS FOR THE IMPROVED PRODUCTION OF PSILOCYBIN AND INTERMEDIATES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | claimed |
| EP-4230195-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC / PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | Arbormentis LLC (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2023081829-A2 | METHODS FOR THE IMPROVED PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS THROUGH ENZYME OPTIMIZATION | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | claimed |
| CN-115052616-A | Methods for producing nudeomushroom elements and intermediates or by-products | 迈阿密大学 | 2022-09-13 | — | — | CN | claimed |
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | Arbormentis LLC (US) | 2022-05-12 | — | — | US | claimed |
| US-12616706-B2 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | Arbormentis LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260102416-A1 | COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF | TLCO HOLDINGS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| EP-4601665-A1 | COMPOSITION COMPRISING TRYPTAMINES AND MAOIS COMPOUNDS SELECTED FROM ?-CARBOLINE INHIBITORS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | disclosed |
| EP-4601655-A1 | DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PSYCHEDELIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | disclosed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | disclosed |
| CN-119899814-A | Three-dimensional crystal structure of compound of PsiM protein, SAH and Norbaeocystin of stropharia rugoso-annulata and application | 中山大学孙逸仙纪念医院 | 2025-04-29 | — | — | CN | disclosed |
| WO-2022272176-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022226493-A1 | OPTIMIZED METHODS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-115052616-A | Methods for producing nudeomushroom elements and intermediates or by-products | 迈阿密大学 | 2022-09-13 | — | — | CN | disclosed |
| EP-4051312-A1 | METHODS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4051312-A1 | METHODS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022150854-A1 | SYSTEMS AND METHODS FOR PHARMACEUTICAL PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022099424-A1 | ENGINEERED MICROORGANISMS FOR PRODUCING SUBSTITUTED TRYPTAMINES | ALGAE-C INC. (CA) | 2022-05-19 | — | — | WO | disclosed |
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | Arbormentis LLC (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616706-B2 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | HTR2C, HTR2A, PNMT | HTR2A 2/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20260102416-A1 | COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF | PDE8B, MGLL, PDE3B | HTR2A 52/4885HTR2C 27/4885HTR2B 29/4885 |
| US-20220143051-A1 | COMPOSITIONS AND METHODS OF USE COMPRISING SUBSTANCES WITH NEURAL PLASTICITY ACTIONS ADMINISTERED AT NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSAGES AND FORMULATIONS | HTR2A, GRIN2A, HTR1A | HTR2A 1/4885HTR2C 4/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.